Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity

Abstract

Activation of tyrosine kinase receptors is associated with human tumors. Tumorigenic versions of several RTKs, such as Ret, Kit and Met carry activating mutations at highly conserved residues of the tyrosine kinase domain. We have investigated the effect of some of these mutations on the NTRK1/NGF receptor, for which no naturally occurring activating point mutations have been so far detected. We introduced the following mutations in NTRK1 tyrosine kinase domain: (i) D668N equivalent to Met D1246N associated to HPRC; (ii) D668V modelled on Kit D816V found in mastocytosis; (iii) M688T corresponding to Ret M918T associated to the cancer syndrome MEN2B. The Met-like mutation rendered the NTRK1 receptor more responsive to ligand, as observed for the corresponding mutation in Met. On the contrary the Kit-like D668V resulted as neutral mutation. Surprisingly, the MEN2B-like M688T completely abrogated NTRK1 receptor activity, resulting as a loss of function mutation. Our results show that the mutations tested, although involving conserved amino acids in highly homologous regions, exert distinct effects in different receptors, and suggest a very peculiar auto-inhibitory mechanism for NTRK1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Cordon-Cardo C, Tapley P, Jing S, Nanduri V, O'Rorke E, Lamballe F, Kovary K, Klein R, Jones KR, Reichardt LF, Barbacid M . 1991 Cell 66: 173–183

  • Cunningham ME, Greene LA . 1998 EMBO J. 17: 7282–7293

  • Descamps S, Lebourhis X, Delehedde M, Boilly B, Hondermarck H . 1998 J. Biol. Chem. 273: 16659–16662

  • Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y . 1993 J. Clin. Invest. 92: 1736–1744

  • Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA . 1995 Mol. Cell. Biol. 15: 6118–6127

  • Greco A, Villa R, Fusetti L, Orlandi R, Pierotti MA . 2000 J. Cell. Physiol. 182: 127–133

  • Hanks SK, Quinn AM, Hunter T . 1988 Science 241: 42–52

  • Hubbard SR . 1997 EMBO J. 16: 5572–5581

  • Indo Y . 2001 Hum. Mutat. 18: 462–471

  • Kaplan DR, Miller FD . 2000 Curr. Opin. Neurobiol. 10: 381–391

  • Maritano D, Accornero P, Bonifaci N, Ponzetto C . 2000 Oncogene 19: 1354–1361

  • Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA . 1999 Int. J. Cancer 81: 417–427

  • Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA, Greco A . 2002 J. Biol. Chem. 277: 6455–6462

  • Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD . 1995 Proc. Natl. Acad. Sci. USA 92: 10560–10564

  • Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S, Sozzi G . 1996 Genes Chrom. Cancer 16: 1–14

  • Reuther GW, Lambert QT, Caligiuri MA, Der CJ . 2000 Mol. Biol. Cell 20: 8655–8666

  • Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G . 1998 Oncogene 17: 741–749

  • Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim URF, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Zbar B, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Lineham WM . 1997 Nat. Genet. 16: 68–73

  • Songyang Z, Carraway III KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC . 1995 Nature 373: 536–539

  • Tagliabue E, Ghirelli C, Lombardi L, Castiglioni F, Asnaghi L, Longhi C, Borrello MG, Aiello P, Menard S . 1999 Int. J. Biol. Markers 14: 68–72

  • Till JH, Ablooglus AJ, Frankel M, Bishop SM, Kohanskii RA, Hubbard SR . 2001 J. Biol. Chem. 276: 10049–10055

  • Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y . 1994 Blood 83: 2619–2626

  • van Heyningen V . 1994 Nature 367: 319–320

  • Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki SJ, Dionne CA, Isaacs JT . 2001 Clin. Cancer Res. 7: 2237–2245

Download references

Acknowledgements

The authors thank Miss Cristina Mazzadi for secretarial assistance and Mrs Maria Teresa Radice for technical help. This work was supported by AIRC (Italian Association for Cancer Research) and by funds of the EC project BIO4 CT98 (0556).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angela Greco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miranda, C., Zanotti, G., Pagliardini, S. et al. Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity. Oncogene 21, 8334–8339 (2002). https://doi.org/10.1038/sj.onc.1206052

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206052

Keywords

This article is cited by

Search

Quick links